|
Powered by Cell Signaling Technology |
Site Information |
---|
DtMAkRNtVIGTPFW SwissProt Entrez-Gene |
Blast this site against: NCBI SwissProt PDB |
Site Group ID: 448899 |
In vivo Characterization | |
---|---|
Methods used to characterize site in vivo: | |
Disease tissue studied: | |
Relevant cell line - cell type - tissue: |
Upstream Regulation | |
---|---|
Regulatory protein: | |
Putative in vivo kinases: | |
Treatments: |
Downstream Regulation | |
---|---|
Effects of modification on MST2: | |
Effects of modification on biological processes: | |
Induce interaction with: |
References | |
---|---|
Sun Y, et al. (2023) MST2 methylation by PRMT5 inhibits Hippo signaling and promotes pancreatic cancer progression. EMBO J 42, e114558
37905571 Curated Info |
|
Li L, et al. (2023) Chaetocin exhibits anticancer effects in esophageal squamous cell carcinoma via activation of hippo pathway. Aging (Albany NY) 15
37319316 Curated Info |
|
Wang K, et al. (2023) WNT5a Signaling through ROR2 Activates the Hippo Pathway to Suppress YAP1 Activity and Tumor Growth. Cancer Res
36622276 Curated Info |
|
Fujibayashi E, et al. (2022) LATS kinases and SLUG regulate the transition to advanced stage in aggressive oral cancer cells. Sci Rep 12, 12363
35859006 Curated Info |
|
Zeng Y, et al. (2022) MARK2 regulates chemotherapeutic responses through class IIa HDAC-YAP axis in pancreatic cancer. Oncogene
35780183 Curated Info |
|
Mohseni M, et al. (2014) A genetic screen identifies an LKB1-MARK signalling axis controlling the Hippo-YAP pathway. Nat Cell Biol 16, 108-17
24362629 Curated Info |
|
Yee KS, et al. (2012) A RASSF1A Polymorphism Restricts p53/p73 Activation and Associates with Poor Survival and Accelerated Age of Onset of Soft Tissue Sarcoma. Cancer Res 72, 2206-17
22389451 Curated Info |
|
Angus L, et al. (2012) Willin/FRMD6 expression activates the Hippo signaling pathway kinases in mammals and antagonizes oncogenic YAP. Oncogene 31, 238-50
21666719 Curated Info |
|
Kilili GK, Kyriakis JM (2010) Mammalian Ste20-like kinase (Mst2) indirectly supports Raf-1/ERK pathway activity via maintenance of protein phosphatase-2A catalytic subunit levels and consequent suppression of inhibitory Raf-1 phosphorylation. J Biol Chem 285, 15076-87
20212043 Curated Info |
|
Romano D, et al. (2010) Proapoptotic kinase MST2 coordinates signaling crosstalk between RASSF1A, Raf-1, and Akt. Cancer Res 70, 1195-203
20086174 Curated Info |
|
Kim D, et al. (2010) Regulation of proapoptotic mammalian ste20-like kinase MST2 by the IGF1-Akt pathway. PLoS One 5, e9616
20231902 Curated Info |
|
Zhou J (2009) CST Curation Set: 7590; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info |
|
Zhou J (2009) CST Curation Set: 7593; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info |
|
Zhou J (2009) CST Curation Set: 7592; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info |
|
Zhou J (2009) CST Curation Set: 7591; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info |
|
Zhou J (2009) CST Curation Set: 7589; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info |
|
Praskova M, Xia F, Avruch J (2008) MOBKL1A/MOBKL1B phosphorylation by MST1 and MST2 inhibits cell proliferation. Curr Biol 18, 311-21
18328708 Curated Info |